Health Plans, Medical Pharmacy / Specialty, Mid-market Accounts, National Accounts, State Government Solutions

READ: Featured Drug Insights: March 2026

March Drug Insights

Your source for all Prime Therapeutics' March 2026 Drug Insights publications.

Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for March 2026 will keep you informed on what’s trending now and trending clinical topics. 


Released March 4, 2026

Watch List

A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are DB-OTO (Regeneron), pariglasgene brecaparvovec and more.


Released March 11, 2026

High-Cost Therapy Profile

Providing a clinical deep dive into a select high-cost drug in the pipeline, this month's profile features Orca-T, an allogeneic T cell immunotherapy. If approved, Orca-T will be the first allogeneic T call immunotherapy for the treatment of hematologic malignancies.


Released March 16, 2026

Oncology Insights

Featuring commentary by Abby Kim, PharmD, BCOP, on developments in the oncology space, this installment reviews insights from the Precision Medicine World Conference (PMWC) and what they mean for the future of oncology. 


Released March 17, 2026

FDA Decisions Expected: April 2026

A breakdown of FDA decisions expected of new drugs anticipated to hit the market, this edition covers baxdrostat, pivekimab sunirine (PVEK) and more.


Released March 23, 2026

Expert Clinical Network Insights: March 2026

Committed to keeping you informed on the latest specialty drug insights from leading experts, this newsletter features insights on the FDA's approval of narsoplimab-wuug in December 2025 for the treatment of adult and pediatric patients (2-years of age and older) with hematopoietic stem cell transplant-associated thrombotic microangiopahty (TA-TMA).


Released March 26, 2026

Trending Topics & Drug Approvals: March 2026

Prime covers hot topics and the latest specialty and traditional drug approvals. The latest edition covers research from the National Center for Health Statistics on the prevalence of overweight and severe obesity in adults, a recent FDA approval of a medical device to promote short-term limited weight loss and more.


Looking for previous 2026 drug insights publications?

Simply click on the month to access past editions of our drug insights.

January 2026
February 2026